Toronto-based charity The Shoebox Project for Women is partnering with Klick Health (its title sponsor) to launch a four-story art installation by Canadian artist Daniel Mazzone to put a spotlight on local women experiencing homelessness. 

Emergent BioSolutions signed a five-year agreement with Providence Therapeutics to develop and manufacture the Canadian biotechnology company’s Covid-19 vaccine candidate for about $90 million.

Health officials are looking into Canadian data that suggests the risk of heart inflammation after Moderna’s Covid-19 shot is occurring at higher rates in younger adults than previously believed.

Young men could be at higher risk of contracting Covid-19 than previously recognized, researchers suggested, citing computer models.

Moderna will construct a state-of-the-art manufacturing facility in Canada in order to provide direct access to mRNA vaccines for the Covid-19 pandemic, as well as future viral threats and respiratory viruses. 

With a new wave of Covid-19 infections fueled by the Delta variant striking countries worldwide, disease experts are scrambling to learn whether the latest version of coronavirus is making people – mainly the unvaccinated – sicker than before.

Toronto-based biotech Deep Genomics landed $180 million in the company’s oversubscribed Series C.

EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, announced the acquisition of Accelera Canada and its partner companies Patient Access Solutions, Podium Strategic Partners Inc. and Advocacy Solutions.

In a roundup of scientific studies on the novel coronavirus, new findings shed light on why chronic lung diseases that block the airways increase patients’ risks for severe Covid-19 and researchers say the blood disorder anemia should probably be added to the list of risk factors for poorer Covid-19 outcomes.

Resverlogix Corp. announced a partnership to support planned commercialization of apabetalone in the United States, Canada (where authorization has been granted to conduct clinical studies of apabetalone for COVID-19) and/or potentially expanding to additional global markets, as Emergency Use Authorization and/or a New Drug Application or equivalent is issued or approved. In preparation for launch, Resverlogix will utilize EVERSANA’s fully integrated commercialization services that include market access, agency services, clinical and commercial field teams, medical science liaisons, channel management, patient services, health economics and outcomes research, and compliance, with each service optimized by data and predictive analytics.